{"id":"combination-of-ivabradine-and-bisoprolol","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bradycardia"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ivabradine's mechanism of action is unique in that it specifically targets the I(f) channel, which is responsible for the pacemaker current in the sinoatrial node. This results in a reduction in heart rate without affecting contractility. Bisoprolol, on the other hand, is a beta-1 selective adrenergic receptor blocker, which means it primarily affects the heart, reducing heart rate and contractility, while minimizing effects on the lungs and other beta-2 receptors.","oneSentence":"Ivabradine works by inhibiting the I(f) channel in the sinoatrial node, reducing heart rate, while bisoprolol acts as a beta-1 selective adrenergic receptor blocker, further reducing heart rate and contractility.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:16.603Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT05580510","phase":"PHASE2, PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":"Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":160},{"nctId":"NCT01868880","phase":"PHASE4","title":"Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing","status":"WITHDRAWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2016-02","conditions":"Heart Rate Control in ICD Patients With Heart Failure","enrollment":""},{"nctId":"NCT03485482","phase":"PHASE3","title":"Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":"Cardiovascular Diseases","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["concor plus procorolan"],"phase":"phase_3","status":"active","brandName":"combination of Ivabradine and bisoprolol","genericName":"combination of Ivabradine and bisoprolol","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivabradine works by inhibiting the I(f) channel in the sinoatrial node, reducing heart rate, while bisoprolol acts as a beta-1 selective adrenergic receptor blocker, further reducing heart rate and contractility. Used for Atrial fibrillation for stroke prevention, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}